Where does Satish Jindal work?

Satish Jindal is General Partner at Advent Life Sciences.

What does Satish Jindal invest in?

Satish Jindal invests in Biotech.

What check size does Satish Jindal write?

Satish Jindal typically writes checks of $25K – $5M.

Where did Satish Jindal go to school?

Satish Jindal studied at Massachusetts Institute of Technology (Post Doctoral Fellow); Department of Biochemistry, Panjab (Ph.D).

Satish Jindal

Investor

General Partner at Advent Life Sciences

Cambridge, Massachusetts

Writes $25K – $5M checks · typically $1M

About

Satish Jindal joined Advent Life Sciences in January 2022, having previously been CEO of BioMotiv, an operating investment fund. He co-founded and led NeoGenesis (acquired by Schering-Plough), co-founded and served as President of Verastem, and co-founded Elicio Therapeutics, and held Vice President and Site Head roles at Schering-Plough and Bristol-Myers Squibb. He completed postdoctoral research at the Whitehead Institute at MIT and holds a PhD in Biochemistry from Punjab University in India.

Invests in

Biotech

Experience

BioMotiv, Epitopea, Calida, Aleta, Allinaire, Elura, ImmunocodexBoard Membercurrent2022 — present
Advent Life SciencesGeneral Partnercurrent2022 — presentBoston, MA
ImmunocodexBoard Member and Co-foundercurrent2014 — presentCambridge, MA
BioMotivCEO2019 — 2021Boston, MA
Elicio TherapeuticsCo-Founder/Founding CEO2010 — 2019Greater Boston Area
Allied-Bristol Life SciencesCEO2014 — 2019
Bristol-Myers SquibbVice President, BMS;2011 — 2014
Verastem, Inc ( VSTM)President/COO; Co-founder2009 — 2011
Schering-Plough Research Institute (now Merck)VP and Site Head2005 — 2008Cambridge, MA
NeoGenesis Pharmaceuticals (acquired by Schering Plough)CEO, Founder, Chairman, BoD1997 — 2005
PerSeptive Biosystems, Inc.Senior Director1995 — 1996
Whitehead Institute for Biomedical research, MITPost-doctoral Fellow1988 — 1992Cambridge, MA

Skills & more

FundraisingLife Sciences27Biotechnology29Drug Discovery8Drug Development10Technology Transfer6Clinical Development10Oncology7Biopharmaceuticals7R&D4Biochemistry8Pharmaceutical Industry16

Languages Hindi · Russian

From Satish's professional profile.

Colleagues at Advent Life Sciences

Alain Huriez

Venture Partner at Advent Life Sciences

Alan Walts

Venture Partner at Advent Life Sciences

Andrea Beesley

Team Assistant at Advent Life Sciences

Bonita Theara

Executive Assistant at Advent Life Sciences

Dominic Schmidt

General Partner at Advent Life Sciences

Don Drakeman

Distinguished Research Professor, biotech entrepreneur, and venture partner

Fraser Murray

Head of Scientific Evaluation at Advent Life Sciences

Gail Jermyn

Investor Relations Partner at Advent Life Sciences

Frequently asked questions

Who is Satish Jindal?: Satish Jindal joined Advent Life Sciences in January 2022, having previously been CEO of BioMotiv, an operating investment fund. He co-founded and led NeoGenesis (acquired by Schering-Plough), co-founded and served as President of Verastem, and co-founded Elicio Therapeutics, and held Vice President and Site Head roles at Schering-Plough and Bristol-Myers Squibb. He completed postdoctoral research at the Whitehead Institute at MIT and holds a PhD in Biochemistry from Punjab University in India.
Where does Satish Jindal work?: Satish Jindal is General Partner at Advent Life Sciences.
What does Satish Jindal invest in?: Satish Jindal invests in Biotech.
What check size does Satish Jindal write?: Satish Jindal typically writes checks of $25K – $5M.
Where did Satish Jindal go to school?: Satish Jindal studied at Massachusetts Institute of Technology (Post Doctoral Fellow); Department of Biochemistry, Panjab (Ph.D).